XML 60 R49.htm IDEA: XBRL DOCUMENT v3.25.3
Sale of Pegzilarginase to Immedica (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jul. 27, 2023
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Proceeds from sale of in-process research and development asset       $ 7,000 $ 0  
Gain recognized within operating expenses   $ 0 $ 0 10,000 0  
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights To Pegzilarginase            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Proceeds from sale of in-process research and development asset $ 15,000          
Contingent consideration $ 100,000          
Gain recognized within operating expenses   0 $ 0 10,000 $ 0  
Receivable outstanding   $ 3,000   $ 3,000   $ 0